Proprietary CoupledCAR™ platform
Our unique CoupledCAR™ platform is designed to overcome the common challenges of treating solid tumors.It enables in vivo expansion of CAR-T cells, significantly enhancing the efficacy of CAR-T therapy for metastatic solid tumors—a major breakthrough in the field.
GCC19CART, the leading product being developed to treat patients with R/R mCRC
Our lead program, GCC19CART, has demonstrated robust clinical activity in treating relapsed/refractory metastatic colorectal cancer (mCRC), with promising data from clinical trials in both China and the United States. GCC19CART has the potential to become the First-in-Class CAR-T product globally approved for the treatment of colorectal cancer.
In the dose-escalation study conducted in China, at dose level 2 (2 x 10^6 CAR-T/kg), the ORR was observed to be 50%, with the mOS exceeding 26 months.
Phase 1 study of GCC19CART is enrolling patients with R/R mCRC in the U.S., at dose level 1(1 x 10^6 CAR-T/kg), among four patients, the objective response rate (ORR) was 50%, with a median overall survival (mOS) of 17 months. At dose level 2(12x 10^6 CAR-T/kg), among five patients, the ORR was 80%, and the mOS has not yet been reached.
The broad pipeline of CAR-T candidates targeting other solid tumor
We’re also expanding our CAR-T candidate portfolio to treat more types of solid tumors, such as prostate cancer（mCRPC）
Better CAR-T Therapy for Solid Tumors
Discover our broad pipeline of CAR-T candidates targeting other solid tumors
